# ORIGINAL RESEARCH The Danish Heart Failure Registry: A Validation Study of Content

Christina Andersen<sup>1</sup>, Inge Schjødt<sup>1</sup>, Anne Nakano<sup>2</sup>, Søren Paaske Johnsen<sup>3</sup>, Kenneth Egstrup<sup>4</sup>, Brian B Løgstrup<sup>1,5</sup>

<sup>1</sup>Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; <sup>2</sup>The Danish Clinical Registries (RKKP), Aarhus, Denmark; <sup>3</sup>Danish Center for Clinical Health Services Research (DACS), Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; <sup>4</sup>Department of Cardiology, Odense University Hospital, Svendborg, Denmark; <sup>5</sup>Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark

Correspondence: Brian B Løgstrup, Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus, 8200, Denmark, Email bbl@skejby.rm.dk

Background: The Danish Heart Failure Registry (DHFR) is a clinical quality database established to monitor and improve the quality of heart failure (HF) care in Denmark.

**Objective:** We examined the validity of the content of the DHFR.

Methods: In a random sample of patients registered in DHFR between the 1st of January 2016 to the 31st of December 2018, we determined the agreement between the information entered in the database and information in the medical records regarding 1) content; 2) sensitivity; 3) specificity; 4) positive predictive values (PPV) as well as negative predictive values (NPV) of all patient characteristics and performance measures obtained in the DHFR.

**Results:** The study population included 453 patients. In general, the content of the DHFR was accurate. Patient characteristics showed high PPV between 93.0% and 99.5% for all variables. Sensitivity ranged from 81.0% to 95.2%, specificity from 79.8% to 99.5% and NPV ranged from 81.4% to 99.0%. The pharmacological performance measures showed high agreement regarding sensitivity (77.4% to 98.6%) and PPV (84.0% to 94.0%). Further, the specificity ranged from 66.7% to 98.0% and NPP ranged from 90.1% to 96.5%. For the non-pharmacological performance measures, patient education showed high sensitivity (98.0%, 95% CI 96.1-99.1) and PPV (94.9% CI: 93.0–96.3), whereas referral to exercise training had a lower sensitivity of 77.8% (CI: 71.6–83.1) and a PPV of 74.5% (CI: 69.6-78.6).

**Conclusion:** Overall, the Danish Heart Failure Registry have a high degree of completeness and validity, making it a valuable tool for clinical epidemiological research in HF.

Keywords: heart failure, database, epidemiology, registries, Danish Heart Failure Registry

#### Introduction

Despite advances in treatment, the syndrome of heart failure (HF) remains a major cause of mortality, hospitalization, and poor quality of life worldwide.<sup>1</sup> The prevalence is approximately 1–2% of the adult population in developed countries, and with a marked rise to >10% for people aged  $\geq$ 70 years.<sup>2</sup> The prevalence of patients with HF is expected to rise in the future owing to better treatment, higher life expectancy in the general population as well as improved survival rates after acute myocardial infarction (AMI).<sup>1</sup>

The Danish Heart Failure Registry (DHFR) was established in 2003 with the intention to monitor and improve the quality of care for patients with incident HF.<sup>3</sup> Since 2005 the DHFR has had nationwide coverage. Reporting to the registry is mandatory for all hospital departments treating patients with incident HF.

Knowledge of data validity is a prerequisite for meaningful use of the collected data. However, little is known about the validity of the DHFR. Data from this register is used in research and decision-making regarding the healthcare system, so it is essential to have valid, complete, and unbiased data. Therefore, we examined the validity of the content recorded in the DHFR.

cc 0 S © 2022 Andersen et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.do epress.com/term by not incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

# Methods

#### Setting

In Denmark, the healthcare system is tax-funded and provides universal healthcare for all 5.8 million Danish residents. The Danish National Health Service provides tax-supported free access to general practitioners and hospital care, outpatient specialty clinics, and partial reimbursement of prescribed medications.<sup>4</sup> All Danish citizens have an assigned unique civil registration number which enables unambiguous individual-level linkage between registers.

#### Data Registration

The DHFR is an internet-based online database. DHFR includes both inpatients and outpatients with incident HF. To optimize the data quality, data are entered by the local staff of the cardiology department, at which the treatment is performed, using the unique civil registration number. The criteria used for a HF diagnosis in the DHFR is defined by the European Society of Cardiology and validated before entering the database by a local cardiologist.<sup>5</sup> The following primary diagnoses (International Classification of Diseases version 10 codes) are screened for inclusion in the DHFR: DI11.0, DI13.0, DI13.2, DI42.0, DI42.6, DI42.7, DI42.9, DI50.0, DI51.0, and DI50.9. Additional inclusion criteria to the DHFR are age of 18 and older, a first-time hospital contact with HF as the primary diagnosis and symptoms of HF, and/or objective signs of HF, and/or clinical response to HF treatment. Exclusion criteria are isolated right-sided HF, HF secondary to valvular heart diseases, non-correctable structural heart diseases, and tachycardia-induced HF. Furthermore, patients discharged with a primary diagnosis of AMI and concomitant HF are excluded. However, these patients will be included if they are later admitted with HF or are referred to an outpatient cardiology clinic for the treatment of HF. The performance measures recorded in the DHFR are related to diagnostic tests performed, pharmaceutical and non-pharmaceutical treatment, readmission within four weeks, and mortality within one year.<sup>3</sup> Furthermore, patient characteristics are registered as well. The full list is included in Table 1.

#### Study Population

We aimed to retrieve and review medical records for a random computer-generated sample of 10 patient records per year per hospital department reporting to the DHFR between the 1st of January 2016 to the 31st of December 2018. All 29 cardiological departments reporting to the DHFR were invited to participate in the study. Eighteen departments accepted the invitation. The reason for no participation was either the legal restrictions due to data protection or lack of response to the invitation. We were unable to retrieve medical records for seven of the patients (1.5%) as they were deleted from the record achieves at the time of the review. In total, 453 patients were eligible for inclusion in the study population (Figure 1).

Included patients covered hospitals in four of the five Danish regions; Central Denmark, Southern Denmark, North Denmark, and Region Zealand, and included both university hospitals and regional hospitals (Figure 2).

# Statistical Analysis

We considered and reviewed the performance measures mentioned in Table 1. We presented categorical variables using frequencies and proportions, and continuous variables using medians and interquartile ranges.

For validation, we assessed the validity of all performance measures in DHFR through review of hospital medical records considered as the golden standard. We included both patients from university and regional hospital cardiac centers. Within each cardiac center, patients were selected randomly regardless of whether data were missing on one or more variables.

Sensitivity and specificity were computed for all variables. We used Wilson's score methods to calculate 95% confidence intervals (CIs). In addition, we constructed  $2\times2$  tables and computed positive predictive values (PPVs) and negative predictive values (NPVs) for each variable. PPV was defined as the number of true positives/(number of true positives + number of false positives). NPV was defined as the number of true negatives/(number of true negatives + number of false negatives).

All medical records were reviewed blinded, with only access to the civil registration number of the patient and the date of enrollment in the DHFR. If data was not obtainable from the medical records, the data point would be marked as

Main Group	Performance Measures	Definition
Basic characteristics	Status of hospital contact	Inpatient or outpatient
	Date of admission/outpatient contact	
	Date of discharge	Only hospitalized patients
	Status of discharge	Alive or dead
Prognostic factors	Acute myocardial infarction	Yes or no
	Stroke	Yes or no
	Diabetes	Yes or no
	COPD	Yes or no
	Hypertension	Yes or no
	Serum creatinine ≥ 150 µmol/L	Yes or no
	Alcohol intake	$\leq$ 7/14 units per week, > 7/14 units per week or NA
	Smoking	Smoker, previous smoker, never smoker or NA
	Echocardiography	Yes, date, or no
Diagnostic test	LVEF value	LVEF <25%, 25% ≤ LVEF ≤ 35%, 35% < LVEF ≤ 40%, 40%
		< LVEF < 50%, ≥ 50%
Functional capacity	NYHA classification	NYHA functional classification I, II, III, IV or NA
Pharmacological therapy	Status of ACEI/ARB inhibitor treatment	Yes or no
	Initiation of ACEI/ARB inhibitor treatment	Yes, date, or no
	Status of beta-blocker treatment	Yes or no
	Initiation of beta-blocker inhibitor treatment	Yes, date, or no
	Status of MRA treatment	Yes or no
	Initiation of MRA inhibitor treatment	Yes, date, or no
Nonpharmacological treatment	Exercise training	Yes, date or no
		Hospital training or training in municipality
	Patient education	Yes, date, or no
Readmission	Acute readmission within 4 weeks	Yes, date, or no
Mortality	Death within one year	Alive or dead, according to the Danish Civil Registration
		System

#### Table I Patient Characteristics

Abbreviations: COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting-enzyme inhibitors; ARB, angiotensin II receptor blockers; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.

unknown and would be excluded from the analysis. Medical records with doubtful conclusion regarding patient characteristics and/or performance measures, were discussed within the study group together with a specialist in cardiology and a clinical nurse specialist with in-depth knowledge of the database. Before the data collection started, we tested the interobserver reproducibility by two independent examinations of 720 variables from 30 random medical records. The test showed a 98.0% correlation between the two observers. The main discrepancies between the two observers were the exact New York Heart Association (NYHA) classification and smoking status.

All analyses were performed with STATA (version 17.0). The randomization of 10 patients within each combination of department and year was performed using SAS' RANUNI function. The present study was approved by the Danish Data Protection Agency (1–16-02-273-20). Every single participating department management/hospital management gave permission for the dissemination of data from the medical records.

#### Results

#### Baseline Characteristics

The demographics and clinical characteristics of the 453 patients included from the DHFR are listed in Table 2. Sixty-five percent (n=295) were males, and the median age was 70.9 years at the time of registration in the DHFR.




Figure I Consort for the patient selection.

#### Validity

Tables 3–5 shows the sensitivity, specificity, and predictive values for the prognostic factors, and performance measures registered in the DHFR compared with the information retrieved from the medical records.

The prognostic variables (AMI, stroke, chronic obstructive pulmonary disease, diabetes, hypertension, and s-creatinine) showed the sensitivity to range from 81.0% to 95.2% and specificity ranged from 79.8% to 99.5%. Furthermore, we observed s high PPV between 93.0% and 99.5% for all variables (Table 3). The highest PPV was seen for hypertension (99.5%; 95% CI:96.6–99.9) and lowest for s-creatinine>150 umol/L (93.8%; 95% CI: 82.9–97.9). The NPVs ranged from 81.4% to 99.0%.

Looking at smoking and drinking habits, especially drinking (>7/14 alcohol units/week) showed low sensitivity (47.2%; 95% CI: 30.4 to 64.5). Sensitivity for both these prognostic factors ranged from 47.2% to 92.8%, specificity ranged from 39.6% to 98.8%. The PPV for smoking status were between 76.0% and 96.2%. The PPV for alcohol consumption (>7/24 alcohol units/week) were low (63.0%; 95% CI: 42.4 to 80.6) (Table 4). The NPV for both smoking status and alcohol consumption ranged between 62.7% to 95.5%.

As shown in Table 5, the performance measures generally showed high PPVs, with 9 out of 10 variables having PPVs above 80%. The diagnostic variables of echocardiography and NYHA assessment within 12 weeks showed high sensitivity (99.8% for both) and high PPVs (99.6% and 92.4%, respectively). However, because of a few observations not having these diagnostic variables assessed, the specificity was low for both echocardiography and NYHA assessment (33.3% and 34.0%), as well as the NPV for echocardiography (50.0%), whereas the NPV for NYHA assessment was 94.4%. The pharmacological treatment variables also showed high agreement regarding sensitivity, ranging from 77.4% to 98.6%, and PPVs, ranging from 84.0% to 94.0%. Furthermore, the specificity ranged from 66.7% to 98.0%, and the NPVs ranged from 90.1% to 96.5%. For




Figure 2 Distribution of Danish heart failure departments included in the validation (green dot = participating; black dot = not participating).

the non-pharmacological treatment variables, patient education showed high sensitivity (98.0%; 95% CI: 96.1–99.1) and PPV (94.9%; 95% CI: 93.0–96.3), whereas referral to physical exercise within 12 weeks was a little lower, with a sensitivity of 77.8% (95% CI: 71.6–83.1) and a PPV of 74.5% (95% CI: 69.6–78.6).

#### Discussion

This is the first validation of the content of the DHFR. We demonstrated a high level of agreement between data on processes of care recorded in the DHFR performed in a random computer-generated sample of patients registered in the DHFR between 1st of January 2016 to the 31st of December 2018. The medical records were used as golden standard. The validity was assessed as sensitivity, specificity and PPV/NPPs.

Despite the generally high levels of validity of data recorded in the DHFR, differences were observed between the various types of processes. For the variables regarding prognostic comorbidities and therapeutic pharmacological treatment, moderate to very high sensitivities, specificities, PPVs, and NPVs were found for all variables. The variables of the prognostic factors regarding smoking habits also showed high to very high sensitivities, specificities, PPVs, and

Table 2	Baseline	Characteristics	for	Patients	Included	(N=
453)						

Characteristics	N (%)
Gender	
Male	295 (65.1)
Female	158 (34.9)
Age (years)	
18–64 years	157 (34.7)
65-80 years	195 (43.0)
≥ 80 years	101 (22.3)
Prognostic factors	
Acute myocardial infarction	156 (34.4)
Stroke	57 (12.6)
Diabetes	101 (22.3)
COPD	79 (17.4)
Hypertension	202 (44.6)
Serum creatinine ≥ 150 μmol/L	52 (11.5)
Alcohol	
$\leq$ 7/14 units per week	386 (85.2)
> 7/14 units per week	27 (6.0)
Unknown	40 (8.8)
Smoking	(0.0)
Smoker	106 (23.4)
Former smoker	208 (45.9)
Never smoker	117 (25.8)
Unknown	22 (4.9)
Echocardiography	
LVEF <25%	106 (23.4)
$25\% \le LVEF \le 35\%$	201 (44.4)
$35\% < LVEF \le 40\%$	91 (20.1)
40% < LVEF < 50%	20 (4.4)
≥ 50%	33 (7.3)
L 50%	2 (0.4)
NYHA Classification	2 (0.4)
NYHA I	62 (13.7)
NYHA II	255 (56.3)
NYHA III	111 (24.5)
NYHA IV	7 (1.5)
Unknown	18 (4.0)
Pharmacological treatment	10 (1.0)
ACEI/ARB inhibitor prior HF diagnosis	272 (60.0)
ACEI/ARB inhibitor initiation within 8 weeks*	160 (35.3)
Beta-blockers prior HF diagnosis	232 (51.2)
Beta-blockers initiated within 12 weeks*	187 (42.3)
MRA prior HF diagnosis MRA initiated within 12 weeks*	56 (12.4) 160 (35.3)
	100 (33.3)
Non-pharmacological treatment	<u>(140)</u>
Exercise training, hospital	65 (14.3)
Exercise training, municipality	81 (17.9)
Patient education	411 (90.7)
Acute readmission 4-week rate of readmission	54 (11.9)
	(11.7) דכ

**Note**: \*within time period after first contact.

**Abbreviations**: COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; HF, heart failure; MRA, mineralocorticoid receptor antagonist.

	И	DHFR	Medical Records		Sensitivity % (95% CI)	PPV, % (95% CI)	Specificity % (95% Cl)	NPV, % (95% CI)
			Yes	No				
АМІ	453	Yes No	149 22	7 275	87.1 (81.2–91.8)	95.5 (91.1–97.8)	97.5 (95.0–99.0)	92.6 (89.4–94.9)
Stroke	453	Yes No	53 	4 385	82.8 (71.3–91.1)	93.0 (83.2–97.3)	99.0 (97.4–99.7)	97.2 (95.3–98.4)
COPD	453	Yes No	63 14	16 360	81.8 (71.4–89.7)	95.7 (93.2–97.6)	79.8 (70.7–96.6)	96.3 (94.1–97.6)
Diabetes	453	Yes No	99 5	2 347	95.2 (89.1–98.4)	98.0 (92.6–99.5)	99.4 (97.6–99.9)	98.6 (96.7–99.4)
Hypertension	453	Yes No	200 47	l 205	81.0 (75.5–85.7)	99.5 (96.6–99.9)	99.5 (97.3–100.0)	81.4 (77.1–85.0)
S-creatinine >150 umol/L	453	Yes No	45 4	3 392	91.8 (80.4–97.7)	93.8 (82.9–97.9)	99.2 (97.8–99.8)	99.0 (97.5–99.6)

#### Table 3 Sensitivity, Specificity and Predictive Values for Comorbidities

Abbreviations: DHFR, Danish Heart Failure Registry; CI, confidence Intervals; PPV, positive predictive value; NPV. negative predictive value; AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease.

	N	DHFR	Medical Records		Sensitivity, % (95% CI)	PPV, % (95% CI)	Specificity, % (95% CI)	NPV, % (95% CI)
			Yes	No				
Never smoker	453	Yes No	99 14	18 322	87.6 (80.1–93.1)	84.6 (76.8–90.6)	94.7 (91.8–96.8)	95.8 (93.1–97.7)
Current smoker	453	Yes No	102 32	4 315	76.1 (68–83.1)	96.2 (90.6–98.6)	98.8 (96.8–98.7)	90.8 (87.2–93.6)
Former smoker	453	Yes No	158 14	50 231	91.9 (86.7–95.5)	76.0 (69.6–81.6)	82.2 (77.2–86.5)	94.3 (90.6–96.8)
< 7/14 alcohol units/week	451	Yes No	320 25	64 42	92.8 (89.5–95.3)	83.3 (79.2–86.9)	39.6 (30.3–49.6)	62.7 (59–74.2)
> 7/14 alcohol units/week	451	Yes No	17 19	10 405	47.2 (30.4–64.5)	63.0 (42.4–80.6)	97.6 (95.6–98.8)	95.5 (93.1–97.3)

 Table 4 Sensitivity, Specificity and Predictive Values for Smoking Status and Alcohol Consumption

Abbreviations: DHFR, Danish Heart Failure Registry; PPV, positive predictive value; NPV, negative predictive value.

NPVs, whereas variables regarding alcohol consumption, referral to physical exercise, and readmission showed moderate low sensitivities, specificities and PPV/NPVs.

As mentioned above, there were notable differences in validity of especially the patient characteristics. The primary reason for the variables yielding low sensitivities, specificities, PPVs, and NPVs, was the incompleteness of documentation on the variable in the medical records. This was, for example, a problem with the variable on alcohol consumption, as information on this variable were missing in 72 patient records at the time of data collection. This could be caused by the lack of record keeping but more likely because the data were inaccessible for the data collector, which consequently could cause the medical records to be a problematic gold standard.

	N	DHFR	Medical Records		Sensitivity, % (95% CI)	PPV, % (95% CI))	Specificity, % (95% Cl)	NPV, % (95% CI)
			Yes	No				
Echocardiography	453	Yes No	449 I	2 I	99.8 (98.8–100.0)	99.6 (99.0–99.8)	33.3 (0.8–90.6)	50.0 (7.4–92.6)
NYHA assessment within 3 months	453	Yes No	402 I	33 17	99.8 (98.6–99.9)	92.4 (909–93.7)	34.0 (21.2–48.8)	94.4 (69.8–99.2)
ACE/ATII inhibitors before HF diagnosis	453	Yes No	243 8	29 173	96.8 (93.8–98.6)	89.3 (85–92.2)	85.6 (80.0–90.2)	95.6 (91.6–97.7)
ACE-/ATII inhibitors started within 8 weeks	173	Yes No	142 2	9 20	98.6 (95.1–99.8)	94.0 (90.2–96.5)	69.0 (49.2–84.7)	90.9 (71.2–97.6)
Betablockers before HF diagnosis	453	Yes No	203 22	29 199	90.2 (85.6–93.8)	87.5 (83.3–90.8)	87.3 (82.3–91.3)	90.1 (85.8–93.1)
Betablockers started within 12 weeks of HF diagnosis	199	Yes No	151 3	15 30	98.1 (94.4–99.6)	90.9 (86.9–93.8)	66.7 (51.1–80.0)	90.9 (79.2–98.9)
MRA before HF diagnosis	453	Yes No	48 14	8 383	77.4 (65.0–87.1)	85.7 (74.9–92.4)	98.0 (65.0–87.1)	96.5 (94.5–97.8)
MRA started within 12 weeks of HF diagnosis	380	Yes No	110 6	38 226	94.8 (89.1–98.1)	84.0 (77.6–88.8)	91.5 (87.3–94.7)	97.4 (94.5–98.8)
Patient education	453	Yes No	390 8	21 34	98.0 (96.1–99.1)	94.9 (93.0–96.3)	61.8 (47.7–74.6)	81.0 (67.5–89.7)
Physical exercise	453	Yes No	168 48	58 179	77.8 (71.6–83.1)	74.2 (69.6–78.6)	75.5 (69.5–80.9)	78.9 (74.2–82.9)
Readmission within 4 weeks	452	Yes No	34 18	19 381	65.4 (50.9–78.0)	65.2 (52.5–74.3)	95.3 (92.7–97.1)	95.5 (93.6–96.9)

 Table 5 Sensitivity, Specificity and Predictive Values for Echocardiography, NYHA Classification, Medical Treatment, Patient Education, Physical Exercise and Readmission

Abbreviations: DHFR, Danish Heart Failure Registry; PPV, positive predictive value; NPV, negative predictive value; NYHA, New York Heart Association Classification; ACE, angiotensin converting enzyme; ATII, angiotensin II; HF, heart failure; MRA, mineralocorticoid receptor antagonist.

Other HF registries are used to monitor the quality of care in HF. For example, European Society of Cardiology started in 2010 to collect data in patients with either chronic or acute HF to describe the clinical epidemiology and the diagnostic and therapeutic approaches applied to these patients.<sup>6–8</sup> The Swedish Heart Failure Registry (SwedeHF) was established in 2001, and since 2003 it has registered patients with chronic HF in Sweden.<sup>9</sup> The strengths of the DHFR are that it is a national, multicenter registry with detailed information on patient characteristics, medical treatment, and outcomes. The diagnosis is validated by clinicians according to guidelines, entered electronically, and further individuallevel data linkage (using the civil registration number) to the Danish Civil Registration System enables complete patient follow-up with accurate accounting for censoring due to emigration or death. Moreover, linkage to other registries provides valuable information on comorbidity, socioeconomic data, and subsequent diagnostic and therapeutic resource utilization, clinical events, and mortality,<sup>4,10–13</sup> Finally, DHFR can be used on a patient level to support the best medical treatment on an individual basis, and by now, a validated registry. Although our study supports the use of DHFR for research and as a monitoring tool for quality of care in patients with incident HF, there are some limitations to be considered. Limitations of this study include using historic medical records as the gold standard. A concrete problem we faced was that the electronic patient journal system in Region Zealand, from May 2016 to November 2017, transitioned from OPUS to Sundhedsplatformen. This caused that the medical records from this period and before were archived and not accessible in their original form. This could have caused loss of information. Furthermore, selected variables may have changed during the years. These changes in reporting standards may partly explain some of the missing values over time. It is possible that the accuracy of the recorded data may vary across reporting hospitals or subtypes of patients; however, this study was not aimed at examining causality and therefore the role of classical confounding was not relevant to consider.

A crucial issue is how to achieve higher accuracy of data in the future. We believe, it is of utmost importance to use the continuous development of automatic digital capture, making it possible to automatically "catch" data directly from the electronic medical records. This would make it possible to link data across data sources and avoid error-prone manual data reporting. This generally high level of accuracy in DHFR will hopefully further increase and impact studies based on these data. Also, as part of a clinical quality database, these valid data can continue to form the basis for evaluations of clinical outcomes and guide clinicians, health authorities and political decisions in Denmark.

However, it is also important to be aware that data validity may change over time. Therefore, validation of a clinical quality database like the DHFR is a continuous process – which should be repeated later.

#### Conclusion

The DHFR provides ongoing prospective registration of incident HF patients in Denmark. Overall, the registry data have high degree of completeness and validity, making it a valuable tool for monitoring quality of care and clinical epidemiological research in HF.

# Abbreviations

HF, heart failure; AMI, acute myocardial infarction; DHFR, Danish Heart Failure Registry; CI, confidence intervals; PPV, positive predictive value; NPV, negative predictive value; NYHA, New York Heart Association.

# Acknowledgments

A heartful thanks goes to all the hardworking clinicians who every day continuously support the registration to the DHFR. Also, great thanks to the staff in the participating departments who helped identify, extract and hand over data from the medical records.

# **Author Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, and in all these areas; took part in drafting, revising and critically reviewed the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

# Funding

This study was supported by The Danish Clinical Registries.

# Disclosure

The authors report no conflicts of interest in this work.

# References

- 1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;03(01):7. doi:10.15420/cfr.2016:25:2
- Ponikowski P, Voors A, Anker SD, et al. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC): developed with the special contribution. *Eur J Hear Fail*. 2016;2016(18):891–975. doi:10.15829/1560-4071-2017-1-7-81
- 3. Schjødt I, Nakano A, Egstrup K, Cerqueira C. The Danish heart failure registry. Clin Epidemiol. 2016;8:497-502. doi:10.2147/CLEP.S99504
- 4. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, Schmidt M, Pedersen L, Sørensen HT. Existing data sources for clinical epidemiology: the Danish National database of reimbursed prescriptions. *Clin Epidemiol*. 2012;4(1):303–313. doi:10.2147/CLEP.S37587
- 5. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
- 6. Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational research programme: the heart failure Pilot survey (ESC-HF Pilot). *Eur J Heart Fail*. 2010;12(10):1076–1084. doi:10.1093/eurjhf/hfq154
- 7. Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational research programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808–817. doi:10.1093/eurjhf/hft050
- 8. Kapelios CJ, Laroche C, Crespo-Leiro MG, et al. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. *Eur J Heart Fail.* 2020;22(8):1424–1437. doi:10.1002/ejhf.1796
- 9. Jonsson A, Edner M, Alehagen U, Dahlström U. Heart failure registry: a valuable tool for improving the management of patients with heart failure. *Eur J Heart Fail*. 2010;12(1):25–31. doi:10.1093/eurjhf/hfp175
- 10. Vinter N, Fawzy AM, Gent D, et al. Social determinants of health and cardiovascular outcomes in patients with heart failure. *Eur J Clin Invest.* 2022;52:e13843. doi:10.1111/eci.13843
- Schjødt I, Johnsen SP, Strömberg A, Devore AD, Valentin JB, Løgstrup BB. Evidence-based process performance measures and clinical outcomes in patients with incident heart failure with reduced ejection fraction: a Danish Nationwide Cohort Study. *Circ Cardiovasc Qual Outcomes*. 2022;15 (4):E007973. doi:10.1161/CIRCOUTCOMES.121.007973
- 12. Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39(7):30-33. doi:10.1177/1403494811401482
- 13. Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7):26-29. doi:10.1177/1403494811399958

**Clinical Epidemiology** 

#### **Dove**press

Publish your work in this journal

Clinical Epidemiology is an international, peer-reviewed, open access, online journal focusing on disease and drug epidemiology, identification of risk factors and screening procedures to develop optimal preventative initiatives and programs. Specific topics include: diagnosis, prognosis, treatment, screening, prevention, risk factor modification, systematic reviews, risk & safety of medical interventions, epidemiology & biostatistical methods, and evaluation of guidelines, translational medicine, health policies & economic evaluations. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.

Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journal